The Unique Clinical Profile of Dystonia in Parkinson Disease
Objective: Characterize clinical features of dystonia and levodopa-related dyskinesias in Parkinson disease (PD). Background: Dystonia affects 30-60% of individuals with PD. [1] Despite recognition as…Heat Map Visualization of Improved Best ON Time in People With Parkinson’s Disease Treated With Foscarbidopa/Foslevodopa
Objective: Assess the impact of foscarbidopa/foslevodopa (CDp/LDp) continuous subcutaneous infusion (CSCI) on the motor states of people with Parkinson’s disease (PD) across 24 hours via…Increase eye blink rate as a motor fluctuation in levodopa-Induced dyskinesia in parkinson’s disease a forgotten indicator of motor fluctuations a case report
Objective: To recognize the increase eye blink rate (EBR) as a potential motor fluctuation (MF) in a PD patient undergoing levodopa treatment Background: A normal…Reduced Falls With ND0612: Supportive Analyses From the BouNDless Phase 3 Study
Objective: Explore potential reasons for the lower rates of falls with ND0612 vs immediate-release levodopa/carbidopa (IR-LD/CD) therapy reported in the BouNDless study. Background: Falls are…Efficacy of Rifaximin as an Adjunct Treatment for Levodopa induced dyskinesia: Preliminary Results
Objective: To evaluate the efficacy of rifaximin as an adjunct treatment for LID (levodopa induced dyskinesia) in patients with PD through a randomized, double-blind, placebo-controlled…Efficacy of ND0612 in Patients at Different Stages of Disease Severity: Subgroup-Analyses From a Randomized, Active-Controlled Study in People With Parkinson’s Disease Experiencing Motor Fluctuations
Objective: To evaluate the efficacy of investigational ND0612 in reducing motor fluctuations in patients with Parkinson’s disease (PD) at different stages of disease and/or symptom…The effect of vortioxetine and mirtazapine on levodopa-induced dyskinesia in a rat model of Parkinson’s disease
Objective: To investigate the effect of vortioxetine and mirtazapine on levodopa-induced dyskinesia (LID) in a rat model of Parkinson’s disease (PD), we analyzed abnormal involuntary movements (AIMs)…Acute dystonic dyskinesias in a patient used fluvoxamine. Case report
Objective: To represent a case of acute dystonic dyskinesias after fluvoxamine use by the patient with obsessive thoughts and movements. Background: In psychiatric clinical practice,…Pharmacokinetic-Pharmacodynamic Modeling of Amantadine Extended-Release Capsule Effects on Dyskinesia in Parkinson Disease
Objective: Evaluate pharmacokinetic/pharmacodynamic (PK/PD) relationships for the delayed- and extended-release (DR/ER) capsule formulation of amantadine [1] in the treatment of levodopa-related dyskinesia in Parkinson disease.…Genetic Variants and Levodopa Response in Parkinson’s Disease: Insights from MAO-B and DAT1 Polymorphisms
Objective: This study aimed to find the association of genetic variations between Parkinson’s disease (PD) patients with and without levodopa-induced dyskinesia (LID). we intended to…
- « Previous Page
- 1
- …
- 7
- 8
- 9
- 10
- 11
- …
- 49
- Next Page »